2nd series of Translational Neuroscience Webinars
We are pleased to announce that EATRIS and NEURATRIS are launching a second series of webinars on Translational Neuroscience tools in March and April of this year. The series will cover the usage of Ultrahigh Field MRI and other biological and technological tools to study these diseases and their potential application in translational medicine. Each webinar will be co-presented with a Research Infrastructure specializing in these tools.
The first one is scheduled on March 26th between 14.00 -15.00.
The webinars will be brought to you by experts in the field and include an audience Q&A session during which attendees can ask questions at the end of the lecture. Please note that all webinars will be recorded and available for later viewing.
Why should you join?
- Learn about the cutting-edge methodological and technical developments in neurodegenerative diseases
- Discover applications in translational research
- Hear and share with experts in their field, coming from different Research Infrastructures
- Identify state-of-the-art facilities for your future projects, both with academia and industry
SESSION 1: to be confirmed
High field MRI in neurodegenerative diseases by Dr. Cyril Poupon (Neurospin/NeurATRIS/EATRIS)
Webinar Description to follow shortly
SESSION 2: In Vivo Preclinical Models: APRIL 17TH 11.00 am – 12.00 (CET);
In vivo preclinical models for the study of neurodegenerative diseases by Dr. Marie-Christine Birling (PHENOMIN-ICS/Celphedia) & Romina Aron Badin (MIRCen/NeurATRIS)
Animal models are an indispensable research tool to understand, assess and treat neurodegenerative diseases. Rodents and non-human primates (NHP) models are particularly important and still need to be further developed. In this webinar, the speakers will dive deeper into how to generate NHP models for Neurodegenerative diseases and how to characterize them, using the example of the preclinical model of Tauopathy (viral overexpression) and the validation of a new gene therapy strategy for Parkinson’s disease: from primate to patient (MPTP model)